


Proximal Differentiation Therapy for KRAS Mutant Lung Adenocarcinoma

November 13, 2017

Questions

- ▶ What is the cell of origin of lung adenocarcinoma?
- ▶ Are distal adenocarcinomas similar to distal lung progenitors?
- ▶ How "plastic" are respiratory epithelial cells?

Distal Epithelium



Differences from intestinal epithelium

- very slow turnover at steady state
- multiple progenitors at steady-state and after injury
 - basal cell, Clara cell, Type II cell
- bronchioalveolar stem cell (BASC) has been described
 - as a stem cell for bronchioles and alveoli and as the cell-of-origin of K-RasG12D-induced adenocarcinoma

Putative BASCs

Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer


Carla F. Bender Kim,¹ Erica L. Jackson,^{1,3}
Amber E. Woolfenden,^{1,2} Sharon Lawrence,¹
Imran Babar,² Sinae Vogel,¹ Denise Crowley,¹
Roderick T. Bronson,⁴ and Tyler Jacks^{1,2,*}

¹Center for Cancer Research and Department
of Biology

²Howard Hughes Medical Institute
Massachusetts Institute of Technology
Cambridge, Massachusetts 02139

Cell, Vol. 121, 823–835, June 17, 2005,

Adenoviral Cre delivered by inhalation




But...

- ▶ Lineage tracing using a Clara cell specific mouse demonstrates *NO* alveolar contribution at steady state or after injury (Rawlins et al. 2009 *Cell Stem Cell*, 4:525-34).
- ▶ Human K-Ras-mutant tumors are exclusively alveolar (Cooper et al. 1997 *J Pathol*, 181: 401-4).
- ▶ A/J mouse chemically-induced tumors (K-Ras) resemble Type II cells via electron microscopy (Belinsky et al 1992 *Cancer Res*, 52: 3164-73).

Hypothesis


Type II cells are another cell-of-origin for K-Ras-induced lung adenocarcinoma

CreER-loxP system: Controlling expression of genes in time and space




We have CC10-CreER and Sftpc-CreER "knock-in" mouse lines


CC10CreER expresses throughout airway and in a subset of Type II cells




Adenoma/Adenocarcinoma Sequence



Lineage Tracing of CC10-Expressing Cells upon K-RasG12D Induction—CC10CreER; Isl K-RasG12D; Isl fGFP Mouse




Induction of K-RasG12D using SpcCreER



C



Summary





Bronchi/Bronchioles: No phenotype
BADJ: CC10+ hyperplasia, CC10+*Foxj1*+ hyperplasia, CC10+Sftpc+ hyperplasia
Alveoli: Sftpc-positive adenoma/adenocarcinoma

Bronchi/Bronchioles: No phenotype
BADJ: No phenotype or very rarely small hyperplasia at late stage
Alveoli: Sftpc-positive adenoma/adenocarcinoma


Next questions

- ▶ Why are Type II cells uniquely able to form tumors when K-Ras is activated?
- ▶ Why are bronchial epithelial cells protected?


K-Ras activation leads to upregulation of Notch



Notch Pathway




Inhibition of Notch by dominant negative DNMAML1 reduces K-RasG12D induced tumorigenesis in CC10-CreER mice



15 weeks after TM

K-RasG12D; Rosa26-f-GFP;CC10-CreER




K-RasG12D; Rosa26-DNMAML1-GFP;CC10-CreER

Immunohistochemical analysis

CC10CreER; KRasG12D; DNMAML-GFP


Large tumors contain no DNMAML-GFP




Small DNMAML-GFP-positive tumors express squamous markers

Notch Overexpression with K-RasG12D

CC10-CreER; Isl-K-RasG12D; ROSA Notch mice




Gamma secretase inhibition affects K-Ras-addicted lung cancer cells



What is regulating Notch?

- ▶ SOX2 ChIP-seq in H520 cells: Notch 1-4 are direct SOX2 targets
- ▶ In microarrays of CC10-CreER; KRas and Sftpc-CreER; Kras tumors, Sox2 is one of the 15 differentially-regulated genes
- ▶ Sox2 expression is highest in the proximal airway and lowest in the alveoli

Sox2/Notch interaction





Rosa Isl-Sox2-IRES-GFP mouse

Evidence That SOX2 Overexpression Is Oncogenic in the Lung


Yun Lu^{1*}, Christopher Futtner^{1*}, Jason R. Rock², Xia Xu¹, Walter Whitworth¹, Brigid L. M. Hogan², Mark W. Onaitis¹⁺

¹Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America, ²Department of Cell Biology, Duke University Medical Center, Durham, North Carolina, United States of America


PLoS ONE June 2010 | Volume 5 | Issue 6



Modulation of Sox2




CC10CreER; KRasG12D; low Sox2 ($\text{Sox2}^{\text{fl}/+}$)



CC10CreER; KRasG12D; high Sox2 (Isl Sox2)

Model




Lung Development–Bipotent Progenitor



Reconstructing lineage hierarchies of the distal lung epithelium using single-cell RNA-seq

Barbara Treutlein^{1*}, Doug G. Brownfield^{2*}, Angela R. Wu¹, Norma F. Neff¹, Gary L. Mantalas¹, F. Hernan Espinoza², Tushar J. Desai³, Mark A. Krasnow² & Stephen R. Quake¹


15 MAY 2014 | VOL 509 | NATURE




Type I/Type II cell marker expression








E12.5 hr BrdU pulse




E12.5 hr Id2 expression



E14.5 Sox9 expression




K-Ras-induced Dedifferentiation




3D co-culture of K-Ras;Spc-CreER;Tdtm



Sftpc-CreER;Rosa-Tm




Sftpc-CreER;Kras;Rosa-Tm




Pdgfra-H2B:GFP



Increased tumor sphere formation in Spc+Pdpn+ cells




RNAseq analysis for Xia




All analysis done locally on my laptop!


RNAseq analysis for Xia



Tdtm vs Pdpn



DP vs Tdtm



DP vs Tdtm

- Top 20 positive signatures from GSEA **Hallmark** Database
 - In other words, those signatures which are highly **enriched** in the Ptdt cells
- NES = Normalized Enrichment Score

| NAME | NES | NOM p-val | FDR q-val | FWER p-val |
|--|----------|-----------|-----------|------------|
| HALLMARK_ALLOGRAFT_REJECTION | 2.274148 | | | |
| HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | 2 | 0 | 0 | 0 |
| HALLMARK_TNFA_SIGNALING_VIA_NFKB | 2.271345 | | | |
| HALLMARK_E2F_TARGETS | 9 | 0 | 0 | 0 |
| HALLMARK_INFLAMMATORY_RESPONSE | 2.150286 | 0 | 0 | 0 |
| HALLMARK_KRAS_SIGNALING_UP | 2.143379 | | | |
| HALLMARK_COMPLEMENT | 2.124931 | 0 | 0 | 0 |
| HALLMARK_G2M_CHECKPOINT | 2.083865 | 0 | 0 | 0 |
| HALLMARK_INTERFERON_GAMMA_RESPONSE | 2.067638 | | | |
| HALLMARK_COAGULATION | 2.062215 | 0 | 0 | 0 |
| HALLMARK_IL6_JAK_STAT3_SIGNALING | 9 | 0 | 0 | 0 |
| HALLMARK_APICAL_JUNCTION | 2.017774 | 0 | 0 | 0 |
| HALLMARK_APOPTOSIS | 2.010304 | | | |
| HALLMARK_IL2_STAT5_SIGNALING | 1.944694 | 0 | 0 | 0 |
| | 8 | 0 | 0 | 0 |
| | 1.934076 | | | |
| | 5 | 0 | 0 | 0 |
| | 1.909298 | | | |
| | 9 | 0 | 0 | 0 |
| | 1.850201 | | | |
| | 6 | 0 | 0 | 0 |

DP vs Tdtm

- Top 20 positive signatures from GSEA *Curated* Database
 - In other words, those signatures which are highly *enriched* in the Pdtd cells
- NES = Normalized Enrichment Score

| NAME | NES | NOM p-val | FDR q-val | FWER p-val |
|---|---------------|-----------|-----------|------------|
| ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER | 2.507377 6 | 0 | 0 | 0 |
| LIAN_LIPA_TARGETS_3M | 2.437594 7 | 0 | 0 | 0 |
| LIAN_LIPA_TARGETS_6M | 2.436695 6 | 0 | 0 | 0 |
| KOBAYASHI_EGFR_SIGNALING_24HR_DN | 2.429503 7 | 0 | 0 | 0 |
| CROONQUIST_NRAS_SIGNALING_DN | 2.416998 6 | 0 | 0 | 0 |
| POOLA_INVASIVE_BREAST_CANCER_UP | 2.416158 7 | 0 | 0 | 0 |
| MCLACHLAN_DENTAL_CARIES_UP | 2.409849 6 | 0 | 0 | 0 |
| SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP | 2.403276 4 | 0 | 0 | 0 |
| CHANG_CYCLING_GENES | 2.40299 | 0 | 0 | 0 |
| HESS_TARGETS_OF_HOXA9_AND_MEIS1_DN | 2.362187 1 | 0 | 0 | 0 |
| KANG_DOXORUBICIN_RESISTANCE_UP | 2.353079 | 0 | 0 | 0 |
| GRAHAM_NORMAL QUIESCENT VS NORMAL DIVIDING_DN | 2.349801 8 | 0 | 0 | 0 |
| VERHAAK_GLIOMA_MESENCHYMAL | 2.344288 6 | 0 | 0 | 0 |

Pdtd vs Tdtm

- Top 20 positive signatures from GSEA **Gene Ontology** Database
 - In other words, those signatures which are highly **enriched** in the Pdtd cells
- NES = Normalized Enrichment Score

| NAME | NES | NOM p-val | FDR q-val | FWER p-val |
|--|----------|-----------|-----------|------------|
| GO_MYELOID_LEUKOCYTE_ACTIVATION | 2.220508 | 0 | 0 | 0 |
| GO_REGULATION_OF_LEUKOCYTE_CHEMOTAXIS | 6 | 0 | 0 | 0 |
| GO_REGULATION_OF_LEUKOCYTE_MIGRATION | 2.209167 | 0 | 0 | 0 |
| GO_LEUKOCYTE_MIGRATION | 2.180438 | 0 | 0 | 0 |
| GO_INFLAMMATORY_RESPONSE | 5 | 0 | 0 | 0 |
| GO_POSITIVE_REGULATION_OF_LEUKOCYTE_MIGRATION | 2.179667 | 0 | 0 | 0 |
| GO_CELL_CHEMOTAXIS | 2.172299 | 0 | 0 | 0 |
| GO_LEUKOCYTE_CHEMOTAXIS | 2.170640 | 0 | 0 | 0 |
| GO_REGULATION_OF_CYTOKINE_SECRETION | 2.169829 | 0 | 0 | 0 |
| GO_LEUKOCYTE_ACTIVATION | 1 | 0 | 0 | 0 |
| GO_CHEMOKINE_MEDIANDED_SIGNALING_PATHWAY | 2.159894 | 0 | 0 | 0 |
| GO_POSITIVE_REGULATION_OF_CYTOKINE_SECRETION | 2.158500 | 0 | 0 | 0 |
| GO_CELL_ACTIVATION | 2.15269 | 0 | 0 | 0 |
| GO_POSITIVE_REGULATION_OF_LEUKOCYTE_CHEMOTAXIS | 2.152483 | 0 | 0 | 0 |
| GO_CELL_CHEMOTAXIS | 2.152576 | 0 | 0 | 0 |
| GO_REGULATION_OF_CYTOKINE_SECRETION | 7 | 0 | 0 | 0 |
| GO_POSITIVE_REGULATION_OF_LEUKOCYTE_ACTIVATION | 2.147237 | 0 | 0 | 0 |
| GO_CELL_ACTIVATION | 2.133005 | 0 | 0 | 0 |
| GO_POSITIVE_REGULATION_OF_LEUKOCYTE_CHEMOTAXIS | 6 | 0 | 0 | 0 |
| GO_REGULATION_OF_CYTOKINE_SECRETION | 2.120372 | 0 | 0 | 0 |

Pdtd vs Tdtm

- Top positive signatures from GSEA *Oncogenic Signatures* Database
 - In other words, those signatures which are highly *enriched* in the Pdtd cells
- NES = Normalized Enrichment Score

| NAME | NES | NOM p-val | FDR q-val | FWER p-val |
|--|---------------|-----------|-----------|------------|
| RPS14_DN.V1_UP | 2.302174 6 | 0 | 0 | 0 |
| CORDENONSI_YAP_CONSERVED_SIGNALATU RE | 2.232320 3 | 0 | 0 | 0 |
| SNF5_DN.V1_UP | 2.109282 | 0 | 0 | 0 |
| ESC_V6.5_UP_EARLY.V1_DN | 2.108703 | 0 | 0 | 0 |
| STK33_SKM_UP | 2.098588 7 | 0 | 0 | 0 |
| RB_P107_DN.V1_UP | 2.073440 8 | 0 | 0 | 0 |
| CSR_LATE_UP.V1_UP | 2.040403 8 | 0 | 0 | 0 |
| BMI1_DN_MEL18_DN.V1_UP | 2.02171 | 0 | 0 | 0 |
| LEF1_UP.V1_UP | 1.995256 7 | 0 | 0 | 0 |
| P53_DN.V1_DN | 1.936386 7 | 0 | 0 | 0 |
| ATF2_S_UP.V1_UP | 1.934966 | 0 | 0 | 0 |
| TGFB_UP.V1_UP | 1.92077 | 0 | 0 | 0 |
| MEL18_DN.V1_UP | 1.911203 6 | 0 | 0 | 0 |
| BRCA1_DN.V1_UP | 1.893171 1 | 0 | 0 | 0 |
| HOXA9_DN.V1_UP | 1.871001 8 | 0 | 0 | 0 |
| STK33_UP | 1.863819 5 | 0 | 0 | 0 |

SOX2 Mimetic

A Small-Molecule Inhibitor of Tgf- β Signaling Replaces Sox2 in Reprogramming by Inducing Nanog

Justin K. Ichida,^{1,3,6} Joel Blanchard,^{1,6} Kelvin Lam,^{1,6} Esther Y. Son,^{1,2,3,5,6} Julia E. Chung,^{1,2,3} Dieter Egli,^{1,3} Kyle M. Loh,¹ Ava C. Carter,^{1,3} Francesco P. Di Giorgio,^{1,3} Kathryn Koszka,^{1,3} Danwei Huangfu,¹ Hidenori Akutsu,⁴ David R. Liu,⁵ Lee L. Rubin,^{1,*} and Kevin Eggan^{1,2,3,*}

¹Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA

²Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA

³Stowers Medical Institute, 1000 East 50th Street, Kansas City, MO 64110, USA

⁴Department of Reproductive Biology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo 157-8535




⁵Howard Hughes Medical Institute and the Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA

⁶These authors contributed equally to this work



*Correspondence: lee_rubin@harvard.edu (L.L.R.), eggan@mcb.harvard.edu (K.E.)

Cell Stem Cell 5, 491–503, November 6, 2009

DOI 10.1016/j.stem.2009.09.012




In vitro culture system




SOX2 Mimetic In Vivo


Survival proportions: Survival of Two groups



In vitro culture of human cells



Type II cells (3D)



Tumor (2D on feeder layer
with ROCK1 inhibitor)

Summary/Conclusions

- ▶ Active Notch is necessary for K-RasG12D-induced lung adenocarcinoma
- ▶ Inhibition of Notch signaling in K-RasG12D-expressing cells leads to squamous differentiation
- ▶ Activation of Notch along with K-RasG12D in bronchial/bronchiolar cells leads to papillary adenocarcinoma
- ▶ Sox2 activation determines K-Ras-induced tumor location by down regulating Notch
- ▶ Both Sox2 over expression and Notch inhibition proximally differentiate Type II cells such that K-Ras activation is not transforming